COMP360 showed rapid, durable efficacy in severe TRD, with about 40% of patients achieving meaningful response and a strong safety profile. Regulatory review is progressing, with launch expected in 2027 and broad commercial preparations underway. Stakeholder enthusiasm is high, and COMP360 is poised to transform TRD care.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.